Hold the phone, bio­phar­ma: FDA-im­posed clin­i­cal holds are on the rise

Are clin­i­cal holds on the rise? Ac­cord­ing to one analy­sis, signs point to yes, and one field, in par­tic­u­lar, is prov­ing a like­ly cul­prit.

Jef­feries’ Michael Yee came out with a note Sun­day de­tail­ing the sharp rise of FDA-im­posed holds over the last 18 to 24 months fol­low­ing a decade of rel­a­tive­ly lit­tle move­ment on that trend. And if things con­tin­ue un­abat­ed, 2022 has the po­ten­tial to eclipse even last year’s mark.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER